RP
RPRX.US Royalty Pharma Plc
- Market cap
- USD 39.5B
- P/E
- 44.9x
- P/B
- 4.46x
- ROE
- 8.9%
- Dividend yield
- 0.96%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RPRX.US undervalued?
Graham numberRPRX.US trades 198.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Royalty Pharma Plc fundamental analysis
No fundamental analysis for Royalty Pharma Plc yet.
Royalty Pharma Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance t…
Full company profileRoyalty Pharma Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Royalty Pharma Plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.88B | 1.60B | 1.79B | 1.81B | 2.12B | 2.29B | 2.24B | 2.35B | 2.26B | 2.38B | 2.66B |
| Gross Profit | 1.88B | 1.60B | 1.79B | 1.81B | 2.12B | 2.29B | 2.24B | 2.35B | 2.26B | 2.38B | 2.30B |
| Operating Income | 723M | 940M | 1.36B | 2.62B | 1.60B | 1.43B | 307M | 1.49B | 1.29B | 1.56B | 1.48B |
| EBITDA | 1.07B | 1.62B | 1.83B | 2.75B | 1.88B | 1.43B | 424M | 1.89B | 1.56B | 1.64B | 1.45B |
| Net Income | 566M | 1.21B | 1.38B | 2.35B | 975M | 620M | 42.8M | 1.13B | 859M | 771M | 610M |
| EPS | 0.93 | 3.42 | 3.89 | 6.63 | 2.60 | 1.49 | 0.10 | 1.88 | 1.45 | 1.37 | 1.09 |
| Balance Sheet | |||||||||||
| Total Assets | 10.5B | 11.4B | 11.4B | 12.4B | 21.1B | 17.5B | 16.8B | 16.4B | 18.2B | 19.6B | 19.5B |
| Total Liabilities | 6.02B | 6.90B | 6.82B | 6.31B | 6.12B | 7.27B | 7.29B | 6.30B | 7.88B | 9.91B | 9.67B |
| Shareholders' Equity | 4.45B | 4.46B | 4.49B | 6.11B | 15.0B | 10.2B | 5.63B | 6.53B | 6.95B | 6.48B | 6.84B |
| Cash & Short-term Investments | 1.67B | 1.38B | 2.39B | 793M | 1.99B | 2.80B | 2.43B | 1.23B | 1.77B | 637M | 545M |
| Total Debt | 5.90B | 6.80B | 6.52B | 6.24B | 6.10B | 14.0B | 7.12B | 6.14B | 7.61B | 8.95B | 8.59B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.6M | 1.42B | 1.62B | 1.67B | 2.03B | 2.02B | 2.14B | 2.99B | 2.77B | 2.49B | 2.84B |
| Capital Expenditure | 0.00 | 2.29B | 270M | 1.72B | 2.20B | 523K | 2.04B | 2.12B | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -872M | 1.35B | -54.1M | -162M | 2.02B | 103M | 872M | 2.77B | 2.49B | 2.84B |
| Ratios | |||||||||||
| ROE | 12.7% | 27.1% | 30.7% | 38.5% | 6.5% | 6.0% | 0.8% | 17.4% | 12.4% | 11.9% | 8.9% |
| ROA | 5.4% | 10.6% | 12.1% | 18.9% | 4.6% | 3.5% | 0.3% | 6.9% | 4.7% | 3.9% | 3.1% |
| Net Profit Margin | 30.1% | 75.7% | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% | 22.9% |
| Debt to Equity | 1.33x | 1.52x | 1.45x | 1.02x | 0.41x | 1.36x | 1.26x | 0.94x | 1.10x | 1.38x | 1.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Royalty Pharma Plc dividends
- Dividend yield
- 0.96%
- Forward dividend
- 0.94 USD
- Payout ratio
- 49.1%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 378M | 0.67 | 49.1% |
| 2024 | USD 376M | 0.63 | 43.8% |
| 2023 | USD 358M | 0.59 | 31.6% |
| 2022 | USD 333M | 0.76 | 778.2% |
| 2021 | USD 285M | 0.69 | 46.0% |
| 2020 | USD 397M | 1.06 | 40.7% |
| 2019 | USD 739M | 2.09 | 31.5% |
| 2018 | USD 814M | 2.30 | 59.1% |
| 2017 | USD 735M | 2.08 | 60.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Royalty Pharma Plc
- Insiders 6.50%
- Institutions 89.92%
- Public & others 3.59%
- Shares outstanding 445M
- Free float 417M
Top funds holding RPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds New Perspective A | 19.3M | 4.34% | -1.57% | Sep 2026 |
| American Funds Capital Inc Bldr A | 7.43M | 1.67% | -13.48% | Sep 2026 |
| American Funds Growth Fd of Amer A | 6.75M | 1.52% | -10.94% | Sep 2026 |
| Morgan Stanley Inst Growth I | 4.91M | 1.10% | -5.74% | Jun 2026 |
| MS INVF US Advantage I | 4.80M | 1.08% | 0.00% | Sep 2026 |
| MS INVF US Growth I | 3.58M | 0.80% | 0.00% | Sep 2026 |
| VictoryShares Free Cash Flow ETF | 3.43M | 0.77% | +0.34% | Oct 2026 |
| T. Rowe Price Value | 3.36M | 0.75% | 0.00% | Sep 2026 |
| Swedbank Robur Aktiefond Pension | 3.05M | 0.68% | -11.57% | Oct 2026 |
| Swedbank Robur Transfer 70 | 2.68M | 0.60% | -11.86% | Oct 2026 |
| T. Rowe Price Health Sciences | 2.62M | 0.59% | +5.81% | Sep 2026 |
| Latitude Global I GBP Acc | 2.48M | 0.56% | +2.75% | Sep 2026 |
| Patient Opportunity C | 2.40M | 0.54% | -4.00% | Sep 2026 |
| Capital Group NewPers LUX Z | 2.37M | 0.53% | -2.27% | Jul 2026 |
| Invesco Discovery Mid Cap Growth Y | 2.12M | 0.48% | +5.82% | Sep 2026 |
| Fidelity Extended Market Index | 2.04M | 0.46% | +7.53% | Sep 2026 |
| BrighthouseI Morgan Stanley Discovery B | 1.90M | 0.43% | 0.00% | Sep 2026 |
| Transamerica Capital Growth A | 1.86M | 0.42% | 0.00% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 1.76M | 0.39% | -0.06% | Oct 2026 |
| American Funds IS® Growth 1 | 1.73M | 0.39% | +4.23% | Sep 2026 |
Top institutions holding RPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 42.9M | 9.64% | -1.47% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 33.9M | 7.61% | -3.90% | Sep 2026 |
| BlackRock Inc | 27.8M | 6.25% | +7.43% | Jun 2026 |
| FMR Inc | 24.5M | 5.51% | -2.54% | Jun 2026 |
| State Street Corp | 12.3M | 2.77% | +12.27% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 11.2M | 2.51% | +478.70% | Jun 2026 |
| Swedbank AB | 10.7M | 2.41% | -7.42% | Jun 2026 |
| Capital World Investors | 9.52M | 2.14% | +18.42% | Jun 2026 |
| Baillie Gifford & Co Limited. | 9.15M | 2.06% | -8.62% | Sep 2026 |
| Geode Capital Management, LLC | 8.06M | 1.81% | +2.39% | Jun 2026 |
| Caledonia (Private) Investments Pty Ltd | 5.78M | 1.30% | -19.43% | Jun 2026 |
| NORGES BANK | 5.34M | 1.20% | +56.29% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.83M | 1.08% | +6.50% | Jun 2026 |
| Northern Trust Corp | 4.72M | 1.06% | +23.90% | Jun 2026 |
| Nordea Investment Mgmt Bank Demark A/s | 4.44M | 1.00% | +72.37% | Sep 2026 |
| Royal London Asset Management Ltd | 4.32M | 0.97% | +13.42% | Jun 2026 |
| AQR Capital Management LLC | 4.31M | 0.97% | +13.84% | Jun 2026 |
| Amvescap Plc. | 4.23M | 0.95% | +12.80% | Jun 2026 |
| Bank of America Corp | 4.15M | 0.93% | +18.70% | Jun 2026 |
| Legal & General Group PLC | 3.80M | 0.85% | +13.01% | Jun 2026 |
Royalty Pharma Plc company profile
- Company name
- Royalty Pharma Plc
- Ticker
- RPRX.US
- ISIN
- GB00BMVP7Y09
- Exchange
- USA Stocks
- Listed since
- Mar 25, 1993
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 100
- Fiscal year end
- December
- Address
- 110 East 59th Street, New York, NY, United States, 10022
- Phone
- 212 883 0200
- Website
- royaltypharma.com
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma Plc management
10- Mr. Pablo LegorretaFounder, Chairman of the Board & CEO · born 1963
- Mr. Terrance P. CoyneExecutive VP & CFO
- Mr. Christopher HiteChairman of Partnering & Investments · born 1967
- Dr. Marshall Jonathan Urist M.D., Ph.D.Head of Research & Investments · born 1976
- Mr. Greg ButzExecutive Vice President of Partnering & Investments
- Mr. Eric Cornelius SchneiderSenior VP & Chief Technology Officer
- Dr. James Folmar Reddoch Ph.D.Executive VP of Investments & Chief Scientific Officer · born 1970
- Mr. George Grofik C.F.A., CPASenior VP and Head of Investor Relations & Communications
- Mr. Arthur Richard McGivern J.D.Executive VP of Investment & Chief Legal Officer · born 1975
- Ms. Molly SawayaExecutive VP & Head of Human Capital